Drug Sponsors

Circassia to acquire Aerocrine and Prosonix

Monday, May 18, 2015 01:03 PM

Circassia Pharmaceuticals has made an all cash offer to acquire Aerocrine, a Swedish company focused on the development and commercialization of medical diagnostic products for use in the diagnosis and management of patients with asthma, for up to $216.4 million.

More... »


Denali Therapeutics launches to study neurodegenerative disease treatments

Friday, May 15, 2015 02:23 PM

Denali Therapeutics, a new California-based biotechnology company focused on developing effective therapies for neurodegenerative diseases, has launched with an initial investment commitment of $217 million. Denali is based on the collaboration of world-class scientists, industry experts and investors. Recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines for Alzheimer's disease, Parkinson's disease, ALS and other neurodegenerative diseases.

More... »


California Life Sciences Association launches, following BayBio, California Healthcare Institute merger

Friday, May 15, 2015 02:18 PM

The California Life Sciences Association (CLSA) has officially launched as a representation for California’s life sciences sector. CLSA now is the largest state and regional life sciences advocacy group in the country, with more than 750 members. The organization advances California’s life sciences innovation ecosystem by advocating for effective national, state and local public policies and supporting entrepreneurs and life sciences businesses. CLSA is the result of a completed merger between BayBio and California Healthcare Institute.

More... »

Pfizer acquires minority interest in AM-Pharma; secures option to acquire company

Wednesday, May 13, 2015 12:15 PM

Pfizer has acquired a minority equity interest in AM-Pharma, a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company.

More... »

Juno Therapeutics acquires Stage Cell Therapeutics

Wednesday, May 13, 2015 12:11 PM

Juno Therapeutics, a Seattle, Wash.-based biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, has acquired Stage Cell Therapeutics, a privately held biotechnology company based in Munich and Göttingen, Germany.

More... »

Moderna launches venture company Elpidera for rare diseases

Wednesday, May 13, 2015 11:57 AM

Moderna Therapeutics, a Cambridge, Mass.-based developer of messenger RNA (mRNA) Therapeutics, has launched Elpidera, a new Moderna venture focused exclusively on the advancement of mRNA-based medicines for the treatment of rare diseases.

More... »

Perrigo acquires Patheon's Mexican operations for $34 million in cash

Wednesday, May 13, 2015 11:54 AM

Perrigo, a consumer goods and pharmaceutical company headquartered in Ireland, has acquired the Mexican operations of Durham, N.C.-based Patheon for $34 million in cash.  The acquisition is expected to be immediately accretive to calendar 2015 adjusted EPS after the exclusion of estimates for intangible amortization and transaction-related costs.

More... »

Baxter BioScience acquires Oncaspar portfolio for leukemia

Wednesday, May 13, 2015 11:51 AM

Baxter International has signed a definitive agreement to acquire the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria. Baxter gains the marketed biologic treatment Oncaspar, the investigational biologic calaspargase pegol and an established oncology infrastructure with clinical and sales resources.

More... »

Alexion Pharmaceuticals expands in Dublin, to add 200 jobs

Monday, May 11, 2015 03:19 PM

Alexion Pharmaceuticals will significantly expand its operations in Ireland by constructing the company's first ever biologics manufacturing facility outside the U.S. This $502.6 million, four-year project, which will be constructed at Alexion's College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, bringing Alexion's total workforce in Ireland to almost 500.

More... »

UNC-Chapel Hill, GSK partner for HIV cure, launch Qura Therapeutics

Monday, May 11, 2015 02:06 PM

The University of North Carolina at Chapel Hill, a global public research university with experience in HIV basic and clinical research, and GlaxoSmithKline have created the dedicated HIV Cure Center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. This unique public-private partnership will redefine the traditional way of conducting research and create a new model to seek the breakthroughs needed to tackle a global health issue.

More... »

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs